Yi Li

Dr. Yi (Robert) Li, PhD, partner, has over fifteen years of Life Sciences experience in venture investment and management, R&D, and corporate development in the China and the U.S.
Prior to joining BioVeda China, Dr. Li was Vice President of Sinogen International, Ltd., (Shanghai, Hong Kong and Shenzhen, China), a biotechnology investment holding company of H&Q Asia Pacific, a venture capital firm with US$1.8 billion under management.
Dr. Li spent nine years with Sinogen during which he evaluated biotech investment opportunities and corporate collaborations throughout China, as well as, the U.S.Prior to Sinogen, Dr. Li was one of the first scientists to join one of the most successful genomics companies in the U.S., Human Genome Sciences, Inc. where he held positions as Associate Director, Protein Therapeutics, and Group Leader, Drug Target Development.
Dr. Li has been advisor to several Chinese and U.S.
biotechnology companies including Sibiono Biotechnology Company (China) and Abmaxis, Inc and Genpharm, Inc. (SF Bay Area U.S.).
He has served on the Board of Directors of Egen Corporation (San Diego, CA), and Shenzhen Kexing Biotech Co. (Shenzhen, China).
Dr. Li is a former Board member of the Sino-American Pharmaceutical Association (SAPA).
He is also an inventor of thirty five issued US patents.
Dr. Li ranked 3rd place in the CUSBEA Scholarship exam and came to the U.S.
in 1985 as part of the CUSBEA program.
Dr. Li received his Ph.D.
in Biochemistry and Molecular Biology from Harvard University, his M.S.
in Cell Biology from Baylor College of Medicine, and B.S.
in Biochemistry from Nanjing University.